Metoprolol Succinat Tad (Metoprolol Succinate)

Metoprolol succinate is a selective β1‑adrenergic blocker indicated for several cardiovascular conditions.

• Hypertension: lowers systolic and diastolic blood pressure to reduce cardiovascular risk.
• Angina pectoris: decreases myocardial oxygen demand, relieving chest pain during exertion.
• Chronic heart failure: improves left‑ventricular function and reduces hospitalisation rates.
• Post‑myocardial infarction: lowers the chance of recurrent infarction and improves long‑term survival.

• Metoprolol succinate selectively antagonises β1‑adrenergic receptors in cardiac tissue, inhibiting catecholamine‑induced stimulation of adenylate cyclase. This reduces cyclic AMP formation, leading to decreased heart rate, contractility, and myocardial oxygen consumption, while also lowering peripheral vascular resistance and blood pressure.

Metoprolol succinate may cause a range of adverse reactions, most of which are dose‑related and reversible upon discontinuation.

Common Side Effects

• Fatigue: feeling unusually tired or weak.
• Dizziness or light‑headedness, especially on standing.
• Bradycardia: slower than normal heart rate.
• Cold extremities: reduced blood flow to hands and feet.
• Gastrointestinal upset: nausea, abdominal discomfort.
• Headache: mild to moderate intensity.

Serious or Rare Side Effects

• Severe bradycardia or heart block requiring medical attention.
• Marked hypotension leading to fainting.
• Bronchospasm in patients with reactive airway disease.
• Depression or mood changes.
• Allergic reactions such as rash, itching or angioedema.
• Worsening heart failure symptoms.

Before initiating therapy, clinicians should evaluate cardiovascular status and consider potential risks.

• Cardiac assessment: confirm stable heart rhythm and function.
• Blood pressure monitoring: check regularly during dose titration.
• Renal function: adjust dose in patients with impaired clearance.
• Concomitant beta‑blockers: avoid duplicate therapy to prevent excessive blockade.
• Discontinuation: taper gradually to prevent rebound hypertension or tachycardia.
• Store at below 25°C: keep in the original container, protect from moisture and direct sunlight.

Metoprolol succinate can interact with several drug classes, influencing its efficacy and safety.

Major Interactions (Avoid)

• Other beta‑blockers: additive cardiac depression.
• Calcium‑channel blockers (verapamil, diltiazem): increased risk of AV‑block and bradycardia.
• Strong CYP2D6 inhibitors (e.g., quinidine, fluoxetine): raise metoprolol plasma levels.

Moderate Interactions (Monitor Closely)

• Diuretics: may potentiate hypotensive effect.
• NSAIDs: can blunt antihypertensive response.
• Antidepressants (SSRIs, SNRIs): monitor for enhanced bradycardia.
• Antidiabetic agents: mask hypoglycaemia symptoms.
• ACE inhibitors or ARBs: watch for additive blood‑pressure lowering.